Inactive Instrument

News CELLCEUTIX OTC Bulletin Board

Equities

CTIX

US15115V1017

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Feb. 01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
2023	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	Feb. 01	CI
Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	Dec. 05	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 20	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024	23-08-28	AQ
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	23-06-21	AQ
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	23-06-21	CI
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing	23-06-05	AQ
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications	23-04-17	AQ
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers	23-03-15	AQ
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	23-03-15	CI
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission	23-02-23	AQ
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	23-02-15	AQ
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-15	CI
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement	23-01-09	AQ
INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)	23-01-04	AQ
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis	22-12-14	AQ
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis	22-12-13	AQ
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	22-12-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CELLCEUTIX OTC Bulletin Board

Equities

CTIX

US15115V1017

Summary

Filters